Strategies and practice for use of nonsteroidal anti-inflammatory drugs

Scandinavian Journal of Rheumatology

Volumn 25, Issue SUPPL. 105, 1996, Pages 29-46

  Peloso, P M ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

gastrointestinal tract; NSAIDs; relative safety

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; ACETYLSALICYLIC ACID; ARTHROTEC; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; PIROXICAM; SULINDAC; TENIDAP;

ARTHRITIS; CLINICAL PRACTICE; HUMAN; REVIEW; CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 0029839680     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009749609097233     Document Type: Article

References (32)

1. Hall RC. Patterns of drug utilization - national and international aspects: drug use in Australia. Acta Med Scmd Suppl 1984; 683:79-80.
2. Dukes MN, Lunde I. The regulatory control of nonsteroidal anti-inflammatory agents. Eur J Clin Pharmacol 1981; 19:3-10. (Pubitemid 11197400)
3. Brooks PM. Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991; 324: 17 16-25.
4. Pincus T, Callahan LF. Clinical use of multiple nonsteroidal anti-inflammatory drug preparations within individual rheumatology private practices. J Rheumatol 1989; 16:1253-8. (Pubitemid 19260118)
5. Swedberg JA, Steinbauer JR. Osteoarthritis. Am Fam Physician 1992; 45:557-68.
6. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330:1368-75. (Pubitemid 24136062)
7. Capell HA, Rennie JAN, Rooney PJ, et al. Patient compliance: a novel method of testing non-steroidal anti-inflammatory analgesics in rheumatoid arthritis. J Rheumatol 1979; 6584-93.
8. Gottlieb NL. The art and science of non-steroidal anti-inflammatory drug selection. Semin Arthritis Rheum 1985; 15(Suppl. 2):1-3. (Pubitemid 16213909)
9. Geis GS, Stead H, Wallenmark C-B, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with RA or OA, and interim reports on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol 1991; 18(Suppl. 28):114.
10. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:768-72.
11. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343 : 1075-8.
12. Bateman DN, NSAIDs: time to re-evaluate gut toxicity. Lancet 1994; 343:1051-2. (Pubitemid 24128199)
13. Inman WHW, Wilton LV, Pearce GL, Waller PC. Prescription-event monitoring of nabumetone. Pharmaceut Med 1990; 4:309-17. (Pubitemid 20358133)
14. Wylie G, Appelboom T, Bolton W, et al. A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. Br J Rheumatol 1995; 34554-63.
15. Verdickt W, Moran C, Hantzschel H, Fraga AM, Stead H, Geis GS. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 2 1 185-91.
16. De Melo Gomes JA. The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastroduodenal tract by endoscopy. Scand J Rheumatol 1992; 21(Suppl. 96):23-31.
17. Bolten W, Melo Gomes JA, Stead H, Geis GS. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31:753-8.
18. Melo Gomes JA, Roth SH, Zeeh J, Bruyn GAW, Woods EM, Geis GS. Double-blind comparison of efficacy and gastroduodenal safety of diclofenadmisoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52:881-5. (Pubitemid 24019145)
19. Kiff PS, Stead H, Morant SV, Shield MJ. Arthrotec, diclofenac and ibuprofen in general practice. Eur J Rheumatol 1994; 14(Supp l):13-7.
20. Geis GS. Overall safety of Arthrotec. Scand J Rheumatol 1992; 21(Supp. 96):33-6.
21. Geis GS. Overall safety of Arthrotec. Presented at the XIIth EULAR Congress of Rheumatology; July 1991; Budapest, Hungary.
22. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149:2061-5. (Pubitemid 19232229)
23. Knill-Jones R, Drummond M, Kohli H, Davies L. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med 1990; 66:63946.
24. de Pouvourville G. The use of misoprostol as a prophylactic treatment in gastric ulceration associated with nonsteroidal anti-inflammatory drugs: An economic evaluation in the French context. Gastroenterol Clin Biol 1991; 15:300-404.
25. Carrin GJ, Torts KF. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs. Rev EpidCmiol Santé Publique 1990; 38:187-99.
26. Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Techno1 Assessment Health Care 1992;8(2):234-44.
27. Festen J, Jacobs J, Neyenhuis A, Snel P. An economic analysis of the prevention of NSAID-induced gastric ulcers by misoprostol in the Netherlands (abstract). Neth J Med 1992; 40(1,2):A2.
28. Gabriel S, Jaakkimainen L, Bombardier C. The costeffectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36:447-59. (Pubitemid 23104031)
29. Gross P, Glasziou P. Economic impact of new cytoprotective drug on NSAID-induced ulceration (abstract). Presented at the World Congresses of Gastroenterology; August 1990; Sydney, Australia.
30. de Pouvourville G, The economic consequences of NSAID-induced gastropathy: The French context. Scand J Rheumatol 1992; (Suppl. 96):57-61.
31. Bergman JF, Pichot L, de Pouvourville G, et al. Prkvention de lsions gastro-duodnales induites par les anti-inflammatoires non stkroidiens: analyse Cconomique partir d'un sondage r6alisC chez 356 mkdecins. Presse Medicale 1991; 21:979-82.
32. Singh G, Ramey D, Morfeld D, Shi H, Fries J. Epidemiology of NSAID-induced gastrointestinal side effects (abstract). Presented at the American College of Rheumatology; October 1995: San Francisco, California.